Addition by subtraction

In this issue of Blood, Larocca and colleagues show for the first time that selected elderly patients with newly diagnosed multiple myeloma benefit from modification of standard myeloma treatment based on their level of frailty, which results in lower toxicity while preserving efficacy.(1)

Automated summary

This study demonstrates that modifying standard myeloma treatment based on frailty levels benefits elderly patients with newly diagnosed multiple myeloma by reducing toxicity while maintaining efficacy.